C:\Program Files\Stnexp\Queries\10524469 (a).str





chain nodes :
7 8 9 11 12 13 31 33 34 38 39
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 21 22 23 24 25 26
chain bonds :
2-7 7-22 8-9 8-12 9-11 12-31 38-39
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 21-22 21-26 22-23
23-24 24-25 25-26
exact/norm bonds :
2-7 7-22 8-9 8-12 9-11 12-31
exact bonds :
38-39
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 21-22 21-26 22-23
23-24 24-25 25-26
isolated ring systems :
containing 1 : 14 : 21 :

G1:[*1],[*2]

G2:Cl,Br,F,I,CH3,H,[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom 11:CLASS
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 31:CLASS 33:CLASS 34:CLASS 36:Atom 37:Atom 38:CLASS
39:CLASS
Generic attributes :
13:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :

Node 13: Limited
C,C5

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10524469.str





chain nodes :

```
7  8  9  11  12  13  31
ring nodes :
1  2  3  4  5  6  14  15  16  17  18  19  21  22  23  24  25  26
chain bonds :
2-7  7-22  8-9  8-12  9-11  12-31
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  21-22
21-26  22-23  23-24  24-25  25-26
exact/norm bonds :
2-7  7-22  8-9  8-12  9-11  12-31
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  21-22
21-26  22-23  23-24  24-25  25-26
isolated ring systems :
containing 1 : 14 : 21 :


G1:[*1],[*2]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:Atom
11:CLASS  12:CLASS  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  31:CLASS
Generic attributes :
13:
Saturation             : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System    : Monocyclic

Element Count :
Node 13: Limited
    C,C5




L3      STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4   QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1              SCR 1840
L2              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.
L4              QUE  L3 AND L1 NOT L2


=> s l4 sss sam
SAMPLE SEARCH INITIATED 22:12:51 FILE 'REGISTRY'
```

```
SAMPLE SCREEN SEARCH COMPLETED -     2940 TO ITERATE

 68.0% PROCESSED     2000 ITERATIONS                                 11 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        55548 TO    62052
PROJECTED ANSWERS:              82 TO      564

L5           11 SEA SSS SAM L3 AND L1 NOT L2

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1840

L6    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L7    SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10524469 (a).str
```





chain nodes :
7 8 9 11 12 13 31 33 34 38 39
ring nodes :
1 2 3 4 5 6 14 15 16 17 18 19 21 22 23 24 25 26
chain bonds :
2-7 7-22 8-9 8-12 9-11 12-31 38-39
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 21-22
21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
2-7 7-22 8-9 8-12 9-11 12-31
exact bonds :

```
38-39
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19  21-22
21-26  22-23  23-24  24-25  25-26
isolated ring systems :
containing 1 : 14 : 21 :


G1:[*1],[*2]

G2:Cl,Br,F,I,CH3,H,[*3]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:Atom
11:CLASS  12:CLASS  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  31:CLASS  33:CLASS  34:CLASS
36:Atom  37:Atom  38:CLASS  39:CLASS
Generic attributes :
13:
Saturation             : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System    : Monocyclic

Element Count :
Node 13: Limited
    C,C5




L8      STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9   QUE L8 AND L6 NOT L7

=> d l9
L9 HAS NO ANSWERS
L6              SCR 1840
L7              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L9              QUE  L8 AND L6 NOT L7


=> s l9 sss sam
SAMPLE SEARCH INITIATED 22:17:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     2940 TO ITERATE

 68.0% PROCESSED     2000 ITERATIONS                                10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        55548 TO    62052
PROJECTED ANSWERS:              64 TO      524

L10          10 SEA SSS SAM L8 AND L6 NOT L7

=> s l9 sss ful
FULL SEARCH INITIATED 22:17:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    60817 TO ITERATE

100.0% PROCESSED    60817 ITERATIONS                                163 ANSWERS
SEARCH TIME: 00.00.02

L11         163 SEA SSS FUL L8 AND L6 NOT L7

=> => s l11
L12          13 L11

=> d l12 1-13 bib,ab,hitstr
```

L12 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:831452 CAPLUS
DN 149:153111
TI Preparation of HIV inhibiting 5,6-substituted pyrimidines
IN Guillemont, Jerome Emile Georges; Mordant, Celine Isabelle
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 48pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008080964	A1	20080710	WO 2007-EP64605	20071228

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2006-127325 A 20061229
OS MARPAT 149:153111
AB Title compds. represented by the formula I [wherein R1 = H, aryl, formyl, alkyl(carbonyl) or alkyloxycarbonyl; R2, R3, R6, R7 = independently H, OH, halo, cycloalkyl, etc.; R4, R8 = independently OH, halo, cycloalkyl, etc.; R5 = pyridyl, amido, aminomethylene, etc.; X = -NR1-, -O-, -CH2- or -S-; and pharmaceutically acceptable addition salts, solvates, or stereochem. isomeric forms thereof] were prepared as HIV inhibitors. For example, II was provided in a multi-step synthesis starting from 4-cyanoaniline•HCl. I were tested for their potency against wild type virus and clin. isolated HIV strains harboring one or more mutations associated with resistance to reverse transcriptase inhibitors.
IT 1037444-89-5P 1037444-91-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of HIV inhibiting 5,6-substituted pyrimidines)
RN 1037444-89-5 CAPLUS
CN 4-Pyrimidinecarboxamide, 6-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-(4-pyridinylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 1037444-91-9 CAPLUS
CN 4-Pyrimidinecarboxamide, 6-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-(2-furanylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1144983 CAPLUS
DN 147:427364
TI Preparation of 5-amidopyrimidines as HIV virus replication inhibitors.
IN Guillemont, Jerome Emile Georges; Paugam, Mikaeel; Delest, Bruno Francois Marie
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 49pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007113254	A1	20071011	WO 2007-EP53111	20070330

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2006-112044 A 20060330
OS MARPAT 147:427364
AB Title compds. [I; R1 = H, aryl, CHO, alkylcarbonyl, alkyl, alkoxycarbonyl; R2, R3, R7, R8 = H, OH, halo, cycloalkyl, alkoxy, CO2H, alkoxycarbonyl, cyano, NO2, amino, (substituted) alkyl, alkenyl, alkynyl, etc.; R4, R9 = OH, halo, cycloalkyl, alkoxy, CO2H, alkoxycarbonyl, CHO, cyano, NO2, amino, heterocyclyl, (substituted) alkyl, alkenyl, alkynyl, etc.; R5 = cycloalkyl, alkoxy, aryl, heterocyclyl, substituted alkyl, etc.; R6 = H, alkyl; NR5R6 = pyrrolidinyl, piperidinyl, morpholinyl, (substituted) piperazinyl; X = NR1, O, CO, CH2, CH(OH), S, SO, SO2], were prepared Thus, title compound (II) (preparation outlined) inhibited infection of MT4 cells by HIV-1 IIIB with pIC50 = 9.10.
IT 951791-90-5P 951791-93-8P 951791-94-9P
951791-95-0P 951791-99-4P 951792-00-0P
951792-01-1P 951792-02-2P 951792-03-3P
951792-04-4P 951792-05-5P 951792-11-3P
951792-27-1P 951792-33-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidopyrimidines as HIV virus replication inhibitors)
RN 951791-90-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-(4-pyridinylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 951791-93-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 951791-94-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-(2-furanylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 951791-95-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-(2-thienylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 951791-99-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-00-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(3-chlorophenyl)methyl]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-01-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-02-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-03-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-04-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(3-bromophenyl)methyl]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-05-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-[[4-(dimethylamino)phenyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-11-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-bromophenyl)methyl]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-27-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 951792-33-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenoxy]-2-[(4-cyanophenyl)amino]-N-(4-pyridinylmethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:703221 CAPLUS
DN 147:118253
TI Aminopyrimidine derivatives inhibiting protein kinase activity, processes for preparing them, and pharmaceutical compositions containing them
IN Park, Boonsaeng; Lee, Mi Jung; Song, Yu-Mi; Lee, Do Young; Lee, Seung Chul; Kim, Cheol Min; Ro, Seonggu; Cho, Joong Myung
PA Crystalgenomics, Inc., S. Korea
SO PCT Int. Appl., 94pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007073117	A1	20070628	WO 2006-KR5661	20061222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	KR 2007066988	A	20070627	KR 2006-132973	20061222
PRAI	KR 2005-127410	A	20051222		
	US 2006-847722P	P	20060927		

OS CASREACT 147:118253
AB The invention relates to aminopyrimidine derivs. I, inhibiting protein kinase activity, processes for preparing them, pharmaceutical prepns. comprising them, and their pharmaceutical use. I inhibit several protein kinases including glycogen synthase kinase 3 (GSK), aurora kinase, etc., to control signal transductions involved in variable disorders such as diabetes, obesity, dementia, cancer, and inflammation. In compds. I, R1 is H, OH, halo, or C1-2 alk(yl|yloxy); R2 is (un)substituted alk(yl|enyl), aryl, etc.; R3 is H, OH, (un)substituted alkyl, etc.; R2 and R3 are fused together with the nitrogen to which they are attached to form a morpholine ring; R4 to R7 are independently H, OH, halo, (un)substituted amine, etc.; R6 is fused together with R5 or R7 to form a dioxorane ring; including pharmaceutically acceptable salts, hydrates, solvates, or isomers thereof. For instance, the invention compound II was prepared by substitution of 2-chloro pyrimidine-4-carbonitrile with 3-ethoxyaniline (71%) followed by hydrolysis (87%) and amidation with cyclohexylamine (63%). Representative examples of I had inhibition IC50 values from about 0.010 μM to about 0.093 μM; EC50 values from about 0.5 μM to about 3.2 μM; and CC50 values of ≥ 18 μM.
IT 943122-19-8P 943122-27-8P 943122-33-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyrimidine derivs. inhibiting protein kinase activity)
RN 943122-19-8 CAPLUS

CN 4-Pyrimidinecarboxamide, 5-chloro-2-[(3-methoxyphenyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 943122-27-8 CAPLUS
CN 4-Pyrimidinecarboxamide, 5-chloro-N-[1-(4-chlorophenyl)propyl]-2-[(3-methoxyphenyl)amino]- (CA INDEX NAME)



RN 943122-33-6 CAPLUS
CN 4-Pyrimidinecarboxamide, N-ethyl-2-[(3-methoxyphenyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:484688 CAPLUS
DN 147:132884
TI Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain
AU Giblin, Gerard M. P.; O'Shaughnessy, Celestine T.; Naylor, Alan; Mitchell, William L.; Eatherton, Andrew J.; Slingsby, Brian P.; Rawlings, D. Anthony; Goldsmith, Paul; Brown, Andrew J.; Haslam, Carl P.; Clayton, Nick M.; Wilson, Alex W.; Chessell, Iain P.; Wittington, Andrew R.; Green, Richard
CS Neurology and GI Centre of Excellence for Drug Discovery, Molecular Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK
SO Journal of Medicinal Chemistry (2007), 50(11), 2597-2600
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 147:132884
AB Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X,(I) as the optimal compound in the series. 35 Has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clin. candidate for this indication.
IT 666260-30-6P 667905-39-7P 667905-40-0P
667905-41-1P 667905-47-7P 667905-48-8P
667905-50-2P 667905-62-6P 667905-65-9P
667905-68-2P 667905-78-4P 667905-79-5P
667905-81-9P 667905-85-3P 667905-86-4P
667905-87-5P 667906-32-3P 942999-96-4P
942999-97-5P 942999-98-6P 943000-00-8P
943000-01-9P 943000-02-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain)
RN 666260-30-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-39-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-methoxyphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-40-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-41-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-cyanophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-47-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-48-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-50-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-62-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-65-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-68-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-78-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-79-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-81-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-85-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3-methoxyphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-86-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-87-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-32-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-cyanophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 942999-96-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-(2-furanylmethyl)-2-(phenylamino)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 942999-97-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-(phenylamino)-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 942999-98-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[4-(1,1-dimethylethyl)phenyl]amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 943000-00-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-(acetylamino)phenyl]amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 943000-01-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[4-(acetylamino)phenyl]amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 943000-02-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-methoxyphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:440209 CAPLUS
DN 144:468191
TI Preparation of phenylpyrimidinecarboxamides as modulators of voltage-gated sodium and calcium channels
IN Martinborough, Esther; Zimmermann, Nicole; Perni, Robert; Arnost, Michael; Bandarage, Upul; Maltais, Francois; Bemis, Guy
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006050476	A2	20060511	WO 2005-US39881	20051103
WO 2006050476	A3	20061019		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060160817	A1	20060720	US 2005-266142	20051103
EP 1809290	A2	20070725	EP 2005-851346	20051103
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008519034	T	20080605	JP 2007-540050	20051103
PRAI US 2004-624716P	P	20041103		
US 2004-624718P	P	20041103		
US 2004-624800P	P	20041103		
WO 2005-US39881	W	20051103		

OS CASREACT 144:468191; MARPAT 144:468191
AB Title compds. I [wherein X = halo, cyano, Me, etc.; n = 1-4; R1, R2 = H, alkyl, cycloalkyl, etc.; R3, R4 = H, alkyl, heterocyclyl, etc.; Y = H or alkyl] and pharmaceutically acceptable salts thereof were prepared as ion channel modulators, especially as voltage-gated sodium and calcium channel inhibitors. For instance, II was synthesized in multiple steps and showed inhibitory activity for CaV 2.2, Nav 1.3 and NaV 1.8 with IC50 values of < 10.0 μM. I and their pharmaceutical compns. are useful for the treatment of various diseases.
IT 886194-48-5P 886194-96-3P 886195-06-8P
886195-65-9P 886196-10-7P 886196-14-1P
886196-39-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of phenylpyrimidinecarboxamides as inhibitors of voltage-gated sodium and calcium channels)
RN 886194-48-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-

(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 886194-96-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-N-(1-methylethyl)-2-[(4-methylphenyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 886195-06-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-(aminocarbonyl)phenyl]amino]-4-(2-fluorophenyl)-N-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 886195-65-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-[(3-hydroxyphenyl)amino]-N-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 886196-10-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-4-(2-fluorophenyl)-N-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 886196-14-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-[(4-fluorophenyl)amino]-N-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)



RN 886196-39-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)amino]-4-(2-fluorophenyl)-N-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)


Cl
NH
F
N
N
C
N
Pr-i
O
CH2
Ph

L12 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:962223 CAPLUS
DN 143:248410
TI Preparation of pyrimidine derivatives as agonists of cannabinoid receptors for the treatment of pain
IN Giblin, Gerard Martin Paul; Mitchell, William Leonard; Naylor, Alan; Wall, Ian David
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005080349	A1	20050901	WO 2005-EP1937	20050222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2004-4105 A 20040224
OS CASREACT 143:248410; MARPAT 143:248410
AB Title compds. I [wherein Y = (un)substituted phenyl; R1, R4 = H, (cyclo)alkyl, haloalkyl; R2 = (un)substituted benzyl; R6 = (un)substituted (cyclo)alkyl; etc. with some limitations, and their pharmaceutically acceptable derivs.] were prepared as agonists of cannabinoid receptors. For example, II was synthesized in several steps and showed agonistic activity against CB1 and CB2 receptors with EC50 values of > 30,000 nM and < 300 nM, resp. Therefore, I and their pharmaceutical compns. are useful in the treatment of diseases, particularly pain, which are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
IT 863323-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonist; preparation of pyrimidine derivs. as agonists of CB2 receptors for the treatment of pain)
RN 863323-36-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-4-(1,1-dimethylethyl)-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:823578 CAPLUS
DN 143:229872
TI Preparation of aminopyri(mi)dinecarboxamide CB2 modulators for use in combination with PDE4 inhibitors for treating pain, immune, inflammatory and rheumatic diseases
IN Green, Richard Howard; Brown, Andrew James; Connor, Helen Elizabeth; Eatherton, Andrew John; Giblin, Gerard Martin Paul; Jandu, Karamjit Singh; Knowles, Richard Graham; Mitchell, William Leonard; Naylor, Alan; O'Shaughnessy, Celestine Theresa; Palombi, Giovanni; Rawlings, Derek Anthony; Slingsby, Brian Peter; Tralau-Stewart, Catherine Jane; Whittington, Andrew Richard; Williamson, Richard Alexander
PA Glaxo Group Limited, UK; Doughty, Jennifer Margaret
SO PCT Int. Appl., 192 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005074939	A1	20050818	WO 2005-GB348	20050201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732561	A1	20061220	EP 2005-702088	20050201
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
	JP 2007520538	T	20070726	JP 2006-551906	20050201
	US 20080132505	A1	20080605	US 2006-597527 ODP	20061102
PRAI	GB 2004-2355	A	20040203		
	WO 2005-GB348	W	20050201		

common inventor/assignee

OS CASREACT 143:229872; MARPAT 143:229872
AB The invention is related to combination of one or more CB2 modulators of formula I [X = CH, N; Y = (un)substituted Ph; R1 = H, cyclo/alkyl, (un)substituted haloalkyl; R2 = C(R7)2R3; R3 = (un)substituted non-aromatic heterocyclyl, cycloalk(en)yl, 5-6 membered aromatic heterocyclyl, etc.; R4 = H, COMe, SO2Me, cyclo/alkyl, (un)substituted haloalkyl; R6 = Me, Cl, CHmFn; n = 1-3; m = 0-2; (n + m) = 3; R7 = H, alkyl; when X = CH, R6 = Cl, or (un)substituted alkyl and R10 = H, or R10 = Cl, or (un)substituted alkyl and R10 = H; and their pharmaceutically acceptable salts] and one or more PDE4 inhibitors useful for treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflammatory disorder, pain, rheumatoid. The invention is also related to the preparation of CB2 modulators I. For example, reacting cyclobutylamine with 6-(2,3-dichlorophenylamino)-4-trifluoromethylnicotinic acid (preparation given) gave II in 81% yield. Selected I had EC50 values of >300 nM but <1000 nM and efficacy value of >50% at the cloned human cannabinoid CB2 receptor. Three formulations are given.

IT 667905-73-9P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-methylpyridin-4-yl)methyl]amide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of aminopyri(mi)dinecarboxamide CB2 modulators for use in combination with PDE4 inhibitors for treating pain, immune, inflammatory and rheumatic diseases)

RN 667905-73-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-methyl-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



IT 666260-30-6P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-37-5P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667905-38-6P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-39-7P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-methoxybenzylamide 667905-40-0P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667905-41-1P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzylamide 667905-42-2P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-43-3P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-44-4P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-45-5P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-46-6P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-47-7P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-48-8P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-49-9P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-50-2P, 2-(2-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-51-3P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667905-52-4P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667905-53-5P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667905-54-6P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667905-55-7P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid

N-[(pyridin-4-yl)methyl]amide 667905-56-8P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667905-57-9P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667905-58-0P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667905-59-1P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667905-60-4P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667905-61-5P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-cyanobenzylamide 667905-62-6P, 2-(4-Cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-64-8P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667905-65-9P, 2-(3-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-66-0P, 2-(2-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-67-1P, 2-(3-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-68-2P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-chlorobenzylamide 667905-69-3P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-ethylamide 667905-70-6P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667905-71-7P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-72-8P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-isobutylbenzylamide 667905-74-0P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-methylpyridin-4-yl)methyl]amide 667905-75-1P, 2-(2-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-76-2P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-cyanobenzyl)amide 667905-77-3P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyrimidin-4-yl)methyl]amide 667905-78-4P, 2-(2-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzylamide 667905-79-5P, 2-(4-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzylamide 667905-80-8P, 2-(4-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-81-9P, 2-(4-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzylamide 667905-82-0P, 2-(4-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-83-1P, 2-(3-Cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-84-2P, 2-(4-Cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-85-3P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(3-methoxybenzyl)amide 667905-86-4P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(2-chlorobenzyl)amide 667905-87-5P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(3-chlorobenzyl)amide 667905-88-6P, 2-(2-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-ethylamide 667905-89-7P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide

667905-90-0P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-91-1P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzylamide 667905-92-2P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-93-3P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-benzyl-N-methylamide 667905-94-4P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-2-yl)methyl]amide 667905-95-5P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-3-yl)methyl]amide 667905-96-6P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(3,5-difluorobenzyl)amide 667905-97-7P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-trifluoromethoxybenzyl)amide 667905-98-8P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-bromobenzyl)amide 667905-99-9P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-cyanobenzyl)amide 667906-01-6P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-cyanobenzyl)amide 667906-02-7P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-cyanobenzyl)amide 667906-03-8P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-cyanobenzyl)amide 667906-04-9P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-cyanobenzyl)amide 667906-05-0P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667906-06-1P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-fluorobenzyl)amide 667906-07-2P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-cyanobenzyl)amide 667906-08-3P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(2-chloro-4-fluorobenzyl)amide 667906-09-4P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(3-chloro-4-fluorobenzyl)amide 667906-10-7P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-fluoro-2-trifluoromethylbenzyl)amide 667906-11-8P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-fluoro-3-trifluoromethylbenzyl)amide 667906-12-9P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyrimidin-4-yl)methyl]amide 667906-13-0P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-methylpyridin-4-yl)methyl]amide 667906-14-1P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-methylbenzyl)amide 667906-16-3P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 3,4-difluorobenzylamide 667906-17-4P, 2-(3-Chloro-4-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-18-5P, 2-(3-Chloro-2-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-19-6P, 2-(5-Chloro-2-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-20-9P, 2-(3,5-Difluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-21-0P, 2-(3-Chloro-4-cyanophenylamino)-4-

trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-22-1P, 2-(3-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(pyridin-4-yl)methyl]amide 667906-23-2P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-24-3P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-25-4P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-27-6P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-28-7P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-29-8P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-30-1P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-31-2P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-fluoropyridin-4-yl)methyl]amide 667906-32-3P, 2-(3-Cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667906-33-4P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide 667906-34-5P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-35-6P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-36-7P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-37-8P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-38-9P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 2,4-difluorobenzylamide 667906-39-0P, 2-[(3-Fluoro-4-trifluoromethylphenyl)amino]-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-40-3P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-carbamoylbenzylamide 667906-41-4P 667906-43-6P, 2-[(3-Chlorophenyl)amino]-4-trifluoromethylpyrimidine-5-carboxylic acid N-((R)-1-phenylethyl)amide 667906-44-7P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(4-fluorobenzyl)-N-methylamide 667906-45-8P, 2-[(3-Chloro-4-trifluoromethoxyphenyl)amino]-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide 667906-46-9P 667906-47-0P 667906-48-1P, 2-[[3,5-Bis(trifluoromethyl)phenyl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid 4-fluorobenzylamide 862535-08-8P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-[(2-methylpyridin-4-yl)methyl]amide hydrochloride 862535-09-9P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tert-butoxycarbonyl)-4-aminobenzylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyri(mi)dinecarboxamide CB2 modulators for use in combination with PDE4 inhibitors for treating pain, immune, inflammatory and rheumatic diseases)

RN 666260-30-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-37-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-38-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-39-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-methoxyphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-40-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-41-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-cyanophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-42-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-43-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-44-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-45-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-46-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-47-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-48-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-49-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-50-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-51-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-52-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-53-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-54-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-55-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-56-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-(4-pyridinylmethyl)-4-

(trifluoromethyl)- (CA INDEX NAME)



RN 667905-57-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-58-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-59-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-60-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-[(4-

fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-61-5 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(3,5-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-62-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-64-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-65-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-66-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-methoxyphenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-67-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-68-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-69-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-ethyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-70-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-71-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-72-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-(2-methylpropyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-74-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(2-methyl-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-75-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-76-2 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(3-fluorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-77-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-(4-pyrimidinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-78-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-79-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-80-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-81-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-82-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-methoxyphenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-83-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-cyanophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-84-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-85-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3-methoxyphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-86-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-87-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-88-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-N-ethyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-89-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-90-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-91-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-92-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-93-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-94-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(2-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-95-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-96-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3,5-difluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-97-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-98-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-bromophenyl)methyl]-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-99-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(4-cyanophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-01-6 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,3-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-02-7 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-03-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,5-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-04-9 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(3,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-05-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-06-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-07-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,6-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-08-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(2-chloro-4-fluorophenyl)methyl]-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-09-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-10-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-11-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-12-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-(4-pyrimidinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-13-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(2-methyl-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-14-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-methylphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-16-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3,4-difluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-17-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-18-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-19-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(5-chloro-2-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-20-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-difluorophenyl)amino]-N-[(4-

fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-21-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-cyanophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-22-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-23-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-24-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-25-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-27-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-28-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-29-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[(2-fluoro-4-

pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-30-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-31-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-32-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-cyanophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-33-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-34-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-35-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-36-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-37-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-[(4-

fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-38-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2,4-difluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-39-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-[[3-fluoro-4-(trifluoromethyl)phenyl]amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-40-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[[4-(aminocarbonyl)phenyl]methyl]-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-41-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-43-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(1R)-1-phenylethyl]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 667906-44-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-N-methyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-45-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-46-9 CAPLUS
CN Benzeneacetic acid, 3-[[5-[[[(4-fluorophenyl)methyl]amino]carbonyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 667906-47-0 CAPLUS
CN Benzoic acid, 3-chloro-5-[[5-[[[(4-fluorophenyl)methyl]amino]carbonyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 667906-48-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3,5-bis(trifluoromethyl)phenyl]amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 862535-08-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-methyl-4-pyridinyl)methyl]-4-(trifluoromethyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 862535-09-9 CAPLUS
CN Carbamic acid, [(4-aminophenyl)methyl][[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:99357 CAPLUS
DN 142:198088
TI Preparation of pyrimidinecarboxamides, pyrimidinylcarbamates and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases
IN Nunes, Joseph J.; Zhu, Xiaotian; Amouzegh, Patricia; Ghiron, Chiara; Johnston, David N.; Power, Eoin Christopher
PA Amgen Inc., USA
SO PCT Int. Appl., 462 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009443	A1	20050203	WO 2004-US20243	20040624
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050209221	A1	20050922	US 2004-875896	20040623
	AU 2004258862	A1	20050203	AU 2004-258862	20040624
	CA 2529734	A1	20050203	CA 2004-2529734	20040624
	EP 1648464	A1	20060426	EP 2004-777011	20040624
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-482375P	P	20030624		
	US 2004-875896	A	20040623		
	WO 2004-US20243	W	20040624		

OS MARPAT 142:198088
AB Pyrimidine and pyridine carboxamides I [wherein X = N or CH; Y = NH, O or S; R1 - R3 = certain (un)substituted monocyclic or bicyclic ring; or pharmaceutically acceptable salts thereof] as well as pyrimidinylcarbamates were prepared as inhibitors of T cell activation. For example, 2,4-dichloropyrimidine-5-carbonyl chloride, obtained by globally chlorination of uracil-5-carboxylic acid monohydrate with PCl5 in POCl3, underwent amidation with 2,6-dimethylaniline, followed by etherification with 3-chlorophenol and subsequent amination with 3-fluoro-4-(3-(4-methyl-1-piperazinyl)propoxy)aniline to give pyrimidinecarboxamide II. Representative compds. I exhibited inhibition with IC50 values of <10 μM in the LCK-homogeneous time resolved fluorescent kinase assay. Therefore, I and pharmaceutical compns. thereof are useful in the treatment of many diseases such as inflammation.
IT 835641-65-1P, 4-[[2-Chloro-4-[(diethylamino)carbonyl]phenyl]oxy]-2-[[3-fluoro-4-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-N-[(2-pyridinyl)methyl]-5-pyrimidinecarboxamide 835641-66-2P, 4-[[2-Chloro-4-[(diethylamino)carbonyl]phenyl]oxy]-2-[[3-fluoro-4-[[3-(1-piperidinyl)propyl]oxy]phenyl]amino]-N-[(2-pyridinyl)methyl]-5-pyrimidinecarboxamide 835641-72-0P, 4-[[2-Chloro-4-

[(diethylamino)carbonyl]phenyl]oxy]-2-[[3-fluoro-4-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-N-((1S)-1-phenylethyl)-5-pyrimidinecarboxamide 835641-73-1P, 4-[[2-Chloro-4-[(diethylamino)carbonyl]phenyl]oxy]-2-[[3-fluoro-4-[[3-(1-piperidinyl)propyl]oxy]phenyl]amino]-N-((1S)-1-phenylethyl)-5-pyrimidinecarboxamide 835642-67-6P, 4-[[2-Chloro-4-[(diethylamino)carbonyl]phenyl]oxy]-2-[[3-fluoro-4-[[3-(4-methyl-1-piperazinyl)propyl]oxy]phenyl]amino]-N-[(5-methyl-3-isoxazolyl)methyl]-5-pyrimidinecarboxamide 835642-68-7P, 4-[[2-Chloro-4-[(diethylamino)carbonyl]phenyl]oxy]-2-[[3-fluoro-4-[[3-(1-piperidinyl)propyl]oxy]phenyl]amino]-N-[(5-methyl-3-isoxazolyl)methyl]-5-pyrimidinecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of pyrimidinecarboxamides and pyrimidinylcarbamates as inhibitors of T cell activation for treatment of inflammatory diseases)

RN 835641-65-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[2-chloro-4-[(diethylamino)carbonyl]phenoxy]-2-[[3-fluoro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 835641-66-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[2-chloro-4-[(diethylamino)carbonyl]phenoxy]-2-[[3-fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]amino]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 835641-72-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[2-chloro-4-[(diethylamino)carbonyl]phenoxy]-2-[[3-fluoro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 835641-73-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[2-chloro-4-[(diethylamino)carbonyl]phenoxy]-2-[[3-fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 835642-67-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[2-chloro-4-[(diethylamino)carbonyl]phenoxy]-2-[[3-fluoro-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



RN 835642-68-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[2-chloro-4-[(diethylamino)carbonyl]phenoxy]-2-[[3-fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]amino]-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:182849 CAPLUS
DN 140:235740
TI Preparation of pyrimidinylcarboxamide compounds as cannabinoid receptor agonist and their use for treatment of pain
IN Eatherton, Andrew John; Giblin, Gerard Martin Paul; Green, Richard Howard; Mitchell, William Leonard; Naylor, Alan; Rawlings, Derek Anthony; Slingsby, Brian Peter; Whittington, Andrew Richard
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English

Applicant's

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018434	A1	20040304	WO 2003-EP9221	20030819
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003260436	A1	20040311	AU 2003-260436	20030819
	EP 1534687	A1	20050601	EP 2003-792390	20030819
	EP 1534687	B1	20060927		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005539036	T	20051222	JP 2004-530223	20030819
	AT 340785	T	20061015	AT 2003-792390	20030819
	EP 1736470	A2	20061227	EP 2006-121095	20030819
	EP 1736470	A3	20070404		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, LT, LV				
	ES 2273077	T3	20070501	ES 2003-792390	20030819
	US 20060247261	A1	20061102	US 2006-524469	20060228
PRAI	GB 2002-19500	A	20020821		
	GB 2003-16332	A	20030711		
	EP 2003-792390	A3	20030819		
	WO 2003-EP9221	W	20030819		

OS MARPAT 140:235740
AB Title compds. I [Y = substituted Ph (1-3 substituents); R1 = H, alkyl, cycloalkyl, haloalkyl; R2 = C(R5)2R3; R3 = (un)substituted aromatic heterocyclyl or aryl group; R4 = H, alkyl, cycloalkyl, haloalkyl, acetyl, SO2Me; R5 = H or alkyl; R6 = Me, Cl, CHxFn where x = 0-2 and n = 1-3 where N and X add up to 3] and pharmaceutical compns. containing these compds. are prepared and disclosed as cannabinoid receptor agonists. Thus, e.g., II, was prepared via substitution of benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate with 3-chloroaniline with subsequent debenzylation of the ester moiety and amidation with benzylamine. I possessed EC50 values ranging from 20 to >1000nM in assays with yeast cells expressing human cannabinoid CB2 receptor. It is further disclosed that I may be particularly useful for the treatment of pain related to cannabinoid

receptor activity.

IT 666260-30-6P 667905-37-5P 667905-38-6P
667905-39-7P 667905-40-0P 667905-41-1P
667905-42-2P 667905-43-3P 667905-44-4P
667905-45-5P 667905-46-6P 667905-47-7P
667905-48-8P 667905-49-9P 667905-50-2P
667905-51-3P 667905-52-4P 667905-53-5P
667905-54-6P 667905-55-7P 667905-56-8P
667905-57-9P 667905-58-0P 667905-59-1P
667905-60-4P 667905-61-5P 667905-62-6P
667905-63-7P 667905-64-8P 667905-65-9P
667905-66-0P 667905-67-1P 667905-68-2P
667905-69-3P 667905-70-6P 667905-71-7P
667905-72-8P 667905-73-9P 667905-74-0P
667905-75-1P 667905-76-2P 667905-77-3P
667905-78-4P 667905-79-5P 667905-80-8P
667905-81-9P 667905-82-0P 667905-83-1P
667905-84-2P 667905-85-3P 667905-86-4P
667905-87-5P 667905-88-6P 667905-89-7P
667905-90-0P 667905-91-1P 667905-92-2P
667905-93-3P 667905-94-4P 667905-95-5P
667905-96-6P 667905-97-7P 667905-98-8P
667905-99-9P 667906-01-6P 667906-02-7P
667906-03-8P 667906-04-9P 667906-05-0P
667906-06-1P 667906-07-2P 667906-08-3P
667906-09-4P 667906-10-7P 667906-11-8P
667906-12-9P 667906-13-0P 667906-14-1P
667906-16-3P 667906-17-4P 667906-18-5P
667906-19-6P 667906-20-9P 667906-21-0P
667906-22-1P 667906-23-2P 667906-24-3P
667906-25-4P 667906-27-6P 667906-28-7P
667906-29-8P 667906-30-1P 667906-31-2P
667906-32-3P 667906-33-4P 667906-34-5P
667906-35-6P 667906-36-7P 667906-37-8P
667906-38-9P 667906-39-0P 667906-40-3P
667906-41-4P 667906-42-5P 667906-43-6P
667906-44-7P 667906-45-8P 667906-46-9P
667906-47-0P 667906-48-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyrimidinylcarboxamide derivs. cannabinoid CB2 receptor agonist activity)

RN 666260-30-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-37-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-38-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-39-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-methoxyphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-40-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-41-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-cyanophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-42-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-43-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-44-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-45-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-46-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-47-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-48-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-49-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-50-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-51-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-52-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-53-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-54-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-55-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-56-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-57-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-58-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-59-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-60-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-61-5 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(3,5-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-62-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-63-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-methyl-4-pyridinyl)methyl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 667905-64-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-65-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-66-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-methoxyphenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-67-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-68-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-69-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-ethyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-70-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-71-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-72-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-(2-methylpropyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-73-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-methyl-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-74-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(2-methyl-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-75-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-76-2 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(3-fluorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-77-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-(4-pyrimidinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-78-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-79-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-80-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-81-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-methoxyphenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-82-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-methoxyphenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-83-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-cyanophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-84-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-cyanophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-85-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3-methoxyphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-86-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-87-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3-chlorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-88-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)amino]-N-ethyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-89-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-90-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-91-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-92-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-93-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-methyl-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-94-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(2-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-95-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-96-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3,5-difluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-97-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-98-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-bromophenyl)methyl]-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667905-99-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(4-cyanophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-01-6 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,3-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-02-7 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-03-8 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,5-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-04-9 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(3,4-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-05-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-(4-

pyridinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-06-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-07-2 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-cyanophenyl)methyl]-2-[(2,6-dichlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-08-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(2-chloro-4-fluorophenyl)methyl]-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-09-4 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-2-[(3-

chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-10-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-11-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-12-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-(4-pyrimidinylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-13-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(2-methyl-4-

pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-14-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-methylphenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-16-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(3,4-difluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-17-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-18-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-19-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(5-chloro-2-fluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-20-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-difluorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-21-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-cyanophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-22-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-methoxyphenyl)amino]-N-(4-pyridinylmethyl)-

4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-23-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-24-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-25-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-27-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-28-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-29-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-30-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-31-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(2-fluoro-4-pyridinyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-32-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-cyanophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-33-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-34-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-35-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-36-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-37-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-38-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(2,4-difluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-39-0 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-[[3-fluoro-4-(trifluoromethyl)phenyl]amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-40-3 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[[4-(aminocarbonyl)phenyl]methyl]-2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-41-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-42-5 CAPLUS
CN Carbamic acid, [4-[[[[2-[(3-chlorophenyl)amino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]amino]methyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 667906-43-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(1R)-1-phenylethyl]-

4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 667906-44-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(4-fluorophenyl)methyl]-N-methyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-45-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 667906-46-9 CAPLUS
CN Benzeneacetic acid, 3-[[5-[[[(4-fluorophenyl)methyl]amino]carbonyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 667906-47-0 CAPLUS
CN Benzoic acid, 3-chloro-5-[[5-[[[(4-fluorophenyl)methyl]amino]carbonyl]-4-(trifluoromethyl)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 667906-48-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3,5-bis(trifluoromethyl)phenyl]amino]-N-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:182848 CAPLUS
DN 140:217658
TI Preparation of aminopyrimidinecarboxamides and their use as CB2-type cannabinoid receptor modulators
IN Eatherton, Andrew John; Giblin, Gerard Martin Paul; Green, Richard Howard; Mitchell, William Leonard; Naylor, Alan; Rawlings, Derek Anthony; Slingsby, Brian Peter; Whittington, Andrew Richard
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English

common inventor/assignee

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018433	A1	20040304	WO 2003-EP9217	20030819
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495880	A1	20040304	CA 2003-2495880	20030819
	AU 2003264076	A1	20040311	AU 2003-264076	20030819
	AU 2003264076	B2	20070920		
	EP 1539712	A1	20050615	EP 2003-792388	20030819
	EP 1539712	B1	20071107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013676	A	20050621	BR 2003-13676	20030819
	JP 2006501228	T	20060112	JP 2004-530220	20030819
	US 20060293354	A1	20061228	US 2003-524470	20030819
	NZ 537886	A	20070531	NZ 2003-537886	20030819
	AT 377591	T	20071115	AT 2003-792388	20030819
	EP 1878725	A2	20080116	EP 2007-119063	20030819
	EP 1878725	A3	20080130		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, LT, LV				
	ES 2295682	T3	20080416	ES 2003-792388	20030819
	ZA 2005000913	A	20060726	ZA 2005-913	20050201
	MX 2005PA01960	A	20050428	MX 2005-PA1960	20050218
	NO 2005001451	A	20050318	NO 2005-1451	20050318
	HK 1079193	A1	20080425	HK 2005-110876	20051129
	AU 2007211954	A1	20070913	AU 2007-211954	20070827
	IN 2007DN09023	A	20080208	IN 2007-DN9023	20071122
PRAI	GB 2002-19501	A	20020821		
	GB 2003-9326	A	20030424		
	AU 2003-264076	A3	20030819		
	EP 2003-792388	A3	20030819		
	WO 2003-EP9217	W	20030819		
	IN 2005-DN295	A3	20050125		

same date as instant appln.

no ODP

OS MARPAT 140:217658

AB This invention relates to novel aminopyrimidinecarboxamides (shown as I; variables defined below; e.g. II), pharmaceutical compns. containing these compds., particularly in nanoparticulate form for increased bioavailability (no data), and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor. For I: Y is Ph, (un)substituted with 1-3 substituents; R1 = H, C1-6 alkyl, C3-6 cycloalkyl and halo-substituted C1-6 alkyl; R2 is (CH2)mR3 where m = 0-1; or R1 and R2 together with N to which they are attached form an (un)substituted 4-8-membered nonarom. heterocyclyl ring; R3 is an (un)substituted 4-8-membered nonarom. heterocyclyl, an (un)substituted C3-8 cycloalkyl, an (un)substituted straight or branched C1-10 alkyl, a C5-7 cycloalkenyl or R5; R4 = H, C1-6 alkyl, C3-6 cycloalkyl, or halo-substituted C1-6 alkyl, COCH3, and SO2Me; R5 is III wherein p = 0-2 and X is CH2 or O; R6 is Me, chloro or CHxFn wherein n = 1-3, x = 0-2 and n and x add up to 3; R7 is OH, C1-6-alkoxy, NR8aR8b, NHCOR9, NHSO2R9, SOqR9; R8a is H or C1-6alkyl; R8b is H or C1-6alkyl; R9 is C1-6alkyl; q is 0-2. Although the methods of preparation are not claimed, .apprx.265 example prepns. are included. For example, 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide was prepared in 3 steps starting substitution of benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate by 3-chloroaniline to give benzyl 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate followed by base hydrolysis to give 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid followed by amide formation with benzylamine. The example compds. had EC50 values >2000 nM and/or efficacy values of <50% at the cloned human cannabinoid CB1 receptor; some of the example compds., e.g. II, had EC50 values 20-300 nM and efficacy values >50% at the cloned human cannabinoid CB2 receptor. Particle size analyses were carried out on 7 examples of I pre- and post-milling, e.g. 13.15 and 0.33 μM, resp., for 2-(4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (cyclopentylmethyl)amide.

IT 666260-30-6P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyrimidinecarboxamides and their use as CB2-type cannabinoid receptor modulators)

RN 666260-30-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:657952 CAPLUS
DN 137:185506
TI Preparation of 2,4-disubstituted pyrimidine-5-carboxamides as KCNQ potassium channel modulators
IN Hewawasam, Piyasena; Dodd, Dharmpal S.; Weaver, Charles D.; Dextraze, Pierre; Gribkoff, Valentin K.; Kinney, Gene G.; Dworetzky, Steven I.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066036	A1	20020829	WO 2002-US4305	20020214
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2438231	A1	20020829	CA 2002-2438231	20020214
	AU 2002243998	A1	20020904	AU 2002-243998	20020214
	US 20020183335	A1	20021205	US 2002-75521	20020214
	EP 1361879	A1	20031119	EP 2002-709517	20020214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2003003841	A2	20040301	HU 2003-3841	20020214
	JP 2005508833	T	20050407	JP 2002-565594	20020214
	MX 2003PA07395	A	20031204	MX 2003-PA7395	20030818
	NO 2003003683	A	20031017	NO 2003-3683	20030819
PRAI	US 2001-269800P	P	20010220		
	WO 2002-US4305	W	20020214		

OS MARPAT 137:185506
AB A method for treatment of disorders responsive to opening of KDNQ channels comprises administration of title compds. (I; R1 = H, halo, alkyl, Ph, phenylalkyl, heterocyclyl, heterocyclylmethyl, cyano, NR2, etc.; R2 = H, alkyl, cycloalkyl, Ph, phenylalkyl, heterocyclyl, NR2, SR, etc.; R3 = H, halo, alkyl; R4 = H, Me, PhCH2; R5 = H, alkyl, cycloalkyl, Ph, phenylalkyl, heterocyclyl, heterocyclylmethyl; R = alkyl, alkynyl, Ph, phenylalkyl, heterocyclyl, heterocyclylmethyl). Thus, 4-cyclohexyl-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid (preparation given) in CH2Cl2 was treated with polymer-supported 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 4-fluorobenzylamine followed by stirring for 16 h to give 4-cyclohexyl-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 4-fluorophenylmethylamide. The latter at 20 μM gave a >200% increase in KCNQ2 current in oocytes.
IT 452097-11-9P 452097-14-2P 452097-15-3P
452097-17-5P 452097-18-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-disubstituted pyrimidine-5-carboxamides as KCNQ

potassium channel modulators)

RN 452097-11-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 452097-14-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 452097-15-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[methyl(4-nitrophenyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 452097-17-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 452097-18-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:589999 CAPLUS
DN 133:177185
TI Preparation of 1-N-alkyl-N-arylpyrimidinamines as CRF inhibitors
IN Aldrich, Paul Edward; Arvanitis, Argyrios Georgios; Bakthavatchalam, Rajagopal; Beck, James Peter; Cheeseman, Robert Scott; Chorvat, Robert John; Gilligan, Paul Joseph; Hodge, Carl Nicholas; Wasserman, Zelda Rakowitz
PA Dupont Pharmaceuticals Company, USA
SO U.S., 96 pp., Cont.-in-part of U.S. Ser. No. 315,660, abandoned.
CODEN: USXXAM
DT Patent
LA English

103

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6107301	A	20000822	US 1997-906349	19970805
	CA 2174080	A1	19950420	CA 1994-2174080	19941006
	HU 74464	A2	19961230	HU 1996-932	19941006
	CN 1142817	A	19970212	CN 1994-194465	19941006
	ZA 9407921	A	19960411	ZA 1994-7921	19941011
	US 6342503	B1	20020129	US 1998-4150	19980107
PRAI	US 1993-134209	B2	19931012		
	US 1994-297274	B2	19940826		
	US 1994-315660	B2	19940929		

OS MARPAT 133:177185
AB The title compds. [I; Y = CR29; R1 = alkyl, alkenyl, alkynyl, etc.; R3 = aryl, haloalkyl, (un)substituted NH2, etc.; J, K, L = CH, CX1; M = CR5; V = N; Z = N; R4 = H, halo, halomethyl, etc.; R4 is taken together with R29 to form a 5-membered ring and is N; X = Cl, Br, I, etc.; X1 = H, Cl, Br, etc.; R5 = halo, alkyl, haloalkyl, etc.] and their pharmaceutically acceptable salts, useful in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alc. withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems, were prepared and formulated. E.g., a 3-step synthesis of I [Y = V = N; Z = CH; J, K, L = CH; M = C(Me); X = Br; R1, R3, R4 = Me] which showed Ki of 501-2000 nM against CRF receptor binding, was given.
IT 169881-53-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-N-alkyl-N-arylpyrimidinamines as CRF inhibitors)
RN 169881-53-2 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-[[2-bromo-4-(1-methylethyl)phenyl]ethylamino]-N-(2-furanylmethyl)-6-methyl- (CA INDEX NAME)



US 6,107,301

EXAMPLE 80

N-(2-bromo-4-(1-methylethyl)phenyl)-N-ethyl-4-(N-2-furylmethyl)-N-methaylaminocarbonyl-6-methylpyrimidinamine



positional isomer:

-C(O)NH-CH2-furyl group is at the 4-position as compared to 5-position in the claim

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:898879 CAPLUS
DN 123:313998
OREF 123:56294h,56295a
TI Preparation of N-phenyl-2-pyrimidinamines and analogs as corticotropin releasing factor antagonists
IN Aldrich, Paul Edward; Arvanitis, Argyrios Georgios; Cheeseman, Robert Scott; Chorvat, Robert John; Christos, Thomas Eugene; Gilligan, Paul Joseph; Grigoriadis, Dimitri Emil; Hodge, Carl Nicholas; Krenitsky, Paul John; et al.
PA du Pont de Nemours, E. I., and Co., USA
SO PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DT Patent
same as #12
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9510506	A1	19950420	WO 1994-US11050	19941006
	W: AU, BR, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2174080	A1	19950420	CA 1994-2174080	19941006
	AU 9480122	A	19950504	AU 1994-80122	19941006
	AU 692484	B2	19980611		
	EP 723533	A1	19960731	EP 1994-931298	19941006
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 74464	A2	19961230	HU 1996-932	19941006
	CN 1142817	A	19970212	CN 1994-194465	19941006
	BR 9407799	A	19970506	BR 1994-7799	19941006
	JP 09504520	T	19970506	JP 1995-511860	19941006
	JP 3398152	B2	20030421		
	RU 2153494	C2	20000727	RU 1996-109047	19941006
	ZA 9407921	A	19960411	ZA 1994-7921	19941011
	FI 9601599	A	19960607	FI 1996-1599	19960411
	NO 9601425	A	19960612	NO 1996-1425	19960411
	US 6342503	B1	20020129	US 1998-4150	19980107
PRAI	US 1993-134209	A	19931012		
	US 1994-297274	A	19940826		
	US 1994-315660		19940929		
	WO 1994-US11050	W	19941006		

OS MARPAT 123:313998
AB Title compds. [I; J,K,L = N or (un)substituted CH; M = N or CR5; R1 = halo, (halo)alkyl, alkoxy, etc.; R3 = halo, alkyl, (hetero)aryl, etc.; R4 = (alkoxy)alkyl, alkanoyloxyalkyl, allyl, etc.; R5 = halo, (ar)alkyl, alkanoyl, etc.; V = CR1a or N; X = halo, alkyl, (hetero)aryl, alkanoyl, etc.; Y = N, CR3a, CR29; Z = N or CR2; R1a,R2,R3a = H, halo, alkyl, halomethyl, cyano; R4R29 = atoms to form a ring] were prepared Thus, 2-chloro-4,6-dimethylpyrimidine was aminated by 2-bromo-4-(1-methylethyl)aniline and the product N-alkylated to give title compound II which had Ki of <500nM against ACTH releasing factor binding at rat cortex preparation in vitro.
IT 169881-53-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenyl-2-pyrimidinamines and analogs as ACTH releasing factor antagonists)

RN 169881-53-2 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-[[2-bromo-4-(1-methylethyl)phenyl]ethylamino]-N-(2-furanylmethyl)-6-methyl- (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    71.81     254.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -10.40     -10.40

STN INTERNATIONAL LOGOFF AT 22:18:40 ON 28 SEP 2008
```